Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
Patent 7008934 Issued on March 7, 2006. Estimated Expiration Date: 
June 26, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
June 26, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorAssigneeApplicationNo. 10183127 filed on 06/26/2002US Classes:514/58, Dextrin or derivative514/225.2, Hetero ring attached directly or indirectly to the phenothiazine ring nitrogen by acyclic nonionic bonding514/225.5, The hetero ring is monocyclic piperidine514/226.2Chalcogen or nitrogen attached indirectly to the phenothiazine ring nitrogen by acyclic nonionic bondingExaminersPrimary: Maier, Leigh C.Attorney, Agent or FirmInternational ClassesA61K 31/724A61K 31/54 AbstractCompositions and methods are provided for reducing adverse reactions as a result of parenteral administration of certain phenothiazine derivatives such as promethazine hydrochloride. The active compound may be admixed with an effective amount of one or more cyclodextrin derivatives, and if desired, one or more non-ionic surfactants such as the partial esters of sorbitol and the polyoxyethylene oxides of long chain fatty acids such as the polysorbates.Other References
| |
